Drugs / UGN-201
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05375903 | Jun 2022 → Jan 2026 | bladder carcinoma in situ | UroGen Pharma Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05055050 | Jan 2022 → Aug 2026 overdue | urinary bladder cancer | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UGN-201 | “UGN-301 + UGN-201 (imiquimod) in combination” NCT05375903 ↗ |
| Known as | imiquimod | “UGN-301 + UGN-201 (imiquimod) in combination” NCT05375903 ↗ |
| Route | Other | “Intravesical 200 mg /50 ml x 1 dose” NCT05055050 ↗ |